Hible G, Daalova P, Gilles A-M, Cherfils J
Laboratoire d'Enzymologie et Biochimie Structurales, bâtiment 34, CNRS, avenue de la Terrasse, 91198 Gif sur Yvette cedex, France.
Biochimie. 2006 Sep;88(9):1157-64. doi: 10.1016/j.biochi.2006.04.002. Epub 2006 Apr 27.
Guanosine monophosphate kinases (GMPK), by catalyzing the phosphorylation of GMP or dGMP, are of dual potential in assisting the activation of anti-viral prodrugs or as candidates for antibiotic strategies. Human GMPK is an obligate step for the activation of acyclic guanosine analogs, such as ganciclovir, which necessitate efficient phosphorylation, while GMPK from bacterial pathogens, in which this enzyme is essential, are potential targets for therapeutic inhibition. Here we analyze these two aspects of GMPK activity with the crystal structures of Escherichia coli GMPK in complex with ganciclovir-monophosphate (GCV-MP) and with a bi-substrate inhibitor, Ap5G. GCV-MP binds as GMP to the GMP-binding domain, which is identical in E. coli and human GMPKs, but unlike the natural substrate fails to stabilize the closed, catalytically-competent conformation of this domain. Comparison with GMP- and GDP-bound GMPK structures identifies the 2'hydroxyl of the ribose moiety as responsible for hooking the GMP-binding domain onto the CORE domain. Absence of this hydroxyl in GCV-MP impairs the stabilization of the active conformation, and explains why GCV-MP is phosphorylated less efficiently than GMP, but as efficiently as dGMP. In contrast, Ap5G is an efficient inhibitor of GMPK. The crystal structure shows that Ap5G locks an incompletely closed conformation of the enzyme, in which the adenine moiety is located outside its expected binding site. Instead, it binds at a subunit interface that is unique to the bacterial enzyme, which is in equilibrium between a dimeric and an hexameric form in solution. This suggests that inhibitors could be designed to bind at this interface such as to prevent nucleotide-induced domain closure. Altogether, these complexes point to domain motions as critical components to be evaluated in therapeutic strategies targeting NMP kinases, with opposite effects depending on whether efficient phosphorylation or inhibition is being sought after.
鸟苷单磷酸激酶(GMPK)通过催化GMP或dGMP的磷酸化,在协助激活抗病毒前体药物或作为抗生素策略的候选药物方面具有双重潜力。人GMPK是激活无环鸟苷类似物(如更昔洛韦)的必要步骤,更昔洛韦需要高效磷酸化,而来自细菌病原体的GMPK(该酶在其中至关重要)是治疗性抑制的潜在靶点。在这里,我们通过大肠杆菌GMPK与单磷酸更昔洛韦(GCV-MP)和双底物抑制剂Ap5G形成的复合物的晶体结构,分析了GMPK活性的这两个方面。GCV-MP以GMP的形式结合到GMP结合结构域,该结构域在大肠杆菌和人GMPK中是相同的,但与天然底物不同,它无法稳定该结构域的闭合、具有催化活性的构象。与结合GMP和GDP的GMPK结构进行比较,确定核糖部分的2'-羟基负责将GMP结合结构域连接到核心结构域上。GCV-MP中缺少这个羟基会损害活性构象的稳定性,并解释了为什么GCV-MP的磷酸化效率低于GMP,但与dGMP一样高效。相比之下,Ap5G是GMPK的有效抑制剂。晶体结构表明,Ap5G锁定了酶的不完全闭合构象,其中腺嘌呤部分位于其预期结合位点之外。相反,它结合在细菌酶特有的亚基界面上,该酶在溶液中以二聚体和六聚体形式处于平衡状态。这表明可以设计抑制剂结合在这个界面上,以防止核苷酸诱导的结构域闭合。总之,这些复合物表明结构域运动是靶向NMP激酶治疗策略中需要评估的关键组成部分,根据是寻求高效磷酸化还是抑制,会产生相反的效果。